AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6785799
Drug: Carbamazepine (200-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (200-600 mg for 1 year)
Trial: 20850365
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg/d) + calcium (500 mg/d) (n=23)
Trial: 20850365
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + calcium (500 mg/d) (n=23)
Trial: 20850365
Drug: Any raloxifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any raloxifene treatment
Trial: 2693405
Drug: Nimodipine 40
RxNorm normalized name: nimodipine 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 40 mg t.i.d.
Trial: 703670
Drug: (+)-Cyanidanol-3 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-Cyanidanol-3 at a dosage of 6 tablets per day (3000 mg per day)
Trial: 703670
Drug: (+)-Cyanidanol-3 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-Cyanidanol-3 at a dosage of 3 X 1 tablet per day
Trial: 703670
Drug: (+)-Cyanidanol-3 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-Cyanidanol-3 at a dosage of 2 X 3 or 3 X 2 tablets per day
Trial: 703670
Drug: (+)-Cyanidanol-3 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (+)-Cyanidanol-3 at all dose levels
Trial: 31775729
Drug: DQTM tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DQTM tablet (Dan Qi Tong Mai tablet) at single doses of up to 5760 mg
Trial: 31775729
Drug: DQTM tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DQTM tablet (Dan Qi Tong Mai tablet) at twice-daily doses of up to 2160 mg for 14 consecutive days
Trial: 31775729
Drug: DQTM tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DQTM tablet
Trial: 26522871
Drug: Supervised aerobic
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised aerobic exercise (45-50 min/week three times a week for four months) plus pharmacotherapy
Trial: 26522871
Drug: Only antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only antidepressant medication
Trial: 20948512
Drug: Behavioral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral and pharmacologic treatment
Trial: 20439549
Drug: Supplements containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplements containing greater than 50% DHA
Trial: 17335293
Drug: Nonsurgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical therapy with chemoradiotherapy
Trial: 2186058
Drug: MK-329 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-329 (10 mg)
Trial: 7194062
Drug: etofylline clofibrate
RxNorm normalized name: etofylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etofylline clofibrate 500 mg daily (2 x 1 capsule)
Trial: 7194062
Drug: etofylline clofibrate
RxNorm normalized name: etofylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etofylline clofibrate 750 mg daily (3 x 1 capsule)
Trial: 30691405
Drug: Multicomponent physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent physical activity program (MEFAP) with twelve 1.5 h-weekly sessions
Trial: 28323916
Drug: Hydrocortisone infusion
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone infusion (0.2 mg/kg/min for 14 hours)
Trial: 16808927
Drug: 480 mg
RxNorm normalized name: magaldrate 480 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 mg EGb 761
Trial: 16808927
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg EGb 761
Trial: 11820148
Drug: Orlistat treatment
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat treatment with diet
Trial: 11570304
Drug: thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thrombolytic therapy
Trial: 31754793
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with pazopanib (800 mg daily for 1 week) and paclitaxel (80 mg/m2 weekly for 18 weeks) followed by maintenance pazopanib
Trial: 31754793
Drug: Single-agent pazopanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent pazopanib
Trial: 23645158
Drug: MgSO4 infusion
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 infusion (15 mg/kg/h)
Trial: 17523581
Drug: Single KPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single KPT group (two addiction counseling sessions with no additional ketamine therapy)
Trial: 15448531
Drug: Basal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal group (12-ml/h basal rate, 0.05-ml patient-controlled bolus dose)
Trial: 15448531
Drug: Basal-bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus group (8-ml/h basal rate, 4-ml bolus dose)
Trial: 15448531
Drug: Bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus group (0.3-ml/h basal rate, 9.9-ml bolus dose)
Trial: 333862
Drug: Biphasic hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic hormone combination (Cyclacur) with 2 mg estradiol valerianate for 11 days, followed by 2 mg estradiol valerianate plus 0.5 mg dl‐norgestrel for 10 days, and a 7-day medication-free period.
Trial: 27353750
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable hydrogel contact lenses worn by CLIDE
Trial: 27353750
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable hydrogel contact lenses worn by NO-CLIDE
Trial: 26032239
Drug: Other Chemotherapeutic
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Chemotherapeutic Agents
Trial: 23377328
Drug: Topical product
RxNorm normalized name: Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical product containing 0.5% ellagic acid and 0.1% salicylic acid
Trial: 21187200
Drug: verum treatment
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verum treatment (acupoint ST-34 stimulation)
Trial: 21187200
Drug: control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control treatment (nonacupoint stimulation)
Trial: 19133707
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 microg/kg plus 2% prilocaine 3 mg/kg
Trial: 19133707
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg plus 2% prilocaine 3 mg/kg
Trial: 19133707
Drug: 2% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% prilocaine 3 mg/kg
Trial: 21244548
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate 20 mg/kg/day
Trial: 21244548
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate 5 mg/kg/day
Trial: 2729944
Drug: Cefmetazole sodium
RxNorm normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefmetazole sodium (0.375 g)
Trial: 2729944
Drug: Cefmetazole sodium
RxNorm normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefmetazole sodium (0.750 g)
Trial: 2729944
Drug: Cefmetazole sodium
RxNorm normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefmetazole sodium (1 g)
Trial: 2729944
Drug: Cefmetazole sodium
RxNorm normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefmetazole sodium (2 g)
Trial: 2729944
Drug: Cefmetazole sodium
RxNorm normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefmetazole sodium (0.375 g to 2 g)
Trial: 30976787
Drug: Uninterrupted edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted edoxaban 60 mg (30 mg for dose reduction)
Trial: 29273578
Drug: Dasiglucagon 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 0.1 mg
Trial: 29273578
Drug: Dasiglucagon 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 0.3 mg
Trial: 29273578
Drug: Dasiglucagon 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasiglucagon 1.0 mg
Trial: 29273578
Drug: GlucaGen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GlucaGen 0.5 mg
Trial: 29273578
Drug: GlucaGen 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GlucaGen 1.0 mg
Trial: 11136281
Drug: OFA (omeprazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFA (omeprazole, furazolidone, amoxicillin)
Trial: 7527421
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) administered at the same time as buserelin-HMG
Trial: 7527421
Drug: No growth
RxNorm normalized name: Mechano growth factor
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: No growth hormone (GH) administered
Trial: 2537003
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum treatment
Trial: 2537003
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum treatment (after switching from placebo)
Trial: 27710596
Drug: Quercetin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (500 mg/day)
Trial: 30646929
Drug: DHEA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA treatment for 4-12 weeks
Trial: 30646929
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 4-12 weeks
Trial: 28556584
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of prednisone (0.8-1.0 mg/kg/day)
Trial: 28556584
Drug: Medium doses
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium doses of prednisone (0.5-0.6 mg/kg/day)
Trial: 23312689
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of levothyroxine (group 1)
Trial: 23312689
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of levothyroxine (group 2)
Trial: 20080830
Drug: Palonosetron (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.25 mg) + Dexamethasone (8 mg) on day 1
Trial: 20080830
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg b.i.d.) on days 2 and 3
Trial: 18389745
Drug: lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lactated Ringer's solution alone (Group B, n=16)
Trial: 18389745
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline and Ringer's solution, 1:1 ratio (Group C, n=15)
Trial: 11022927
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy (n=76)
Trial: 11022927
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant treatment (control group, n=74)
Trial: 8792046
Drug: Tension night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tension night splint (TNS) in addition to standard treatment (anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Trial: 8792046
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment: anti-inflammatory medication, Viscoheel sofspot heel cushion, stretching program)
Trial: 3736637
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hyperprolactinemia
Trial: 29519882
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (after transfer of 25 participants)
Trial: 25230304
Drug: Intracoronary anisodamine
RxNorm normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary anisodamine (1 mg/5 ml) and diltiazem (2 mg/5 ml)
Trial: 25230304
Drug: Saline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (5 ml) and diltiazem (2 mg/5 ml)
Trial: 18841263
Drug: rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (4 mg/day to 8 mg/day)
Trial: 18841263
Drug: metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (500 mg/day to 2000 mg/day)
Trial: 18841263
Drug: glyburide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glyburide (5 mg/day to 20 mg/day)
Trial: 15932703
Drug: Tongxinluo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo capsule
Trial: 11834429
Drug: Fasting with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting with GH receptor blockade (pegvisomant)
Trial: 11834429
Drug: Fasting without
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting without GH receptor blockade
Trial: 10612300
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (5 mcg every 2 weeks for 8 doses, plus 1 i.m. dose at month 12)
Trial: 10612300
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (20 mcg for 4 doses at months 0, 1, 2, and 12)
Trial: 7821102
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg erythromycin
Trial: 31289971
Drug: Tooth whitening
RxNorm normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Tooth Whitening Strip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth whitening with a photo-activated whitening gel
Trial: 31744060
Drug: Eggplant powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eggplant powder (1.2 g/day; 2.3 mg of ACh/day) for 12 weeks
Trial: 25543296
Drug: c-PACT (curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: c-PACT (curcumin at 1.5 mg.mL(‐1) with blue LED light)
Trial: 23112214
Drug: Balanced starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced starch (HES, 130/0.4, 6%) solution
Trial: 20209995
Drug: Balanced crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced crystalloid solution
Trial: 20924633
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of G-CSF (lenograstim, 100 μg)
Trial: 20924633
Drug: G-CSF (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (100 μg) administered every other day
Trial: 19183141
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of paroxetine (Paxil)
Trial: 16813531
Drug: Risedronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (5 mg/day, orally)
Trial: 2008949
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg midazolam
Trial: 1763599
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg fentanyl
Trial: 8487239
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with MPA 5.0 mg for 12 days of each 25-day cycle plus CEE 0.625 mg daily
Trial: 8487239
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with MPA 2.5 mg daily for 12 treatment cycles plus CEE 0.625 mg daily
Trial: 8487239
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with MPA 5.0 mg daily for 12 treatment cycles plus CEE 0.625 mg daily
Trial: 8487239
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (sequential and continuous)
Trial: 3302998
Drug: Piroxicam, 20
RxNorm normalized name: Piroxicam, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam, 20 mg daily, orally for 10 days
Trial: 29227377
Drug: Chlorthalidone 12.5
RxNorm normalized name: chlorthalidone 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 12.5 mg and Amiloride 2.5 mg once a day
Trial: 17888078
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (60-min infusions)
Trial: 17888078
Drug: Intravenous lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous lacosamide (30-min infusions)
Trial: 17888078
Drug: Oral lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral lacosamide (control)
Trial: 12538372
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 20 mg bd i.v.
Trial: 12538372
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium 40 mg bd i.v.
Trial: 11515622
Drug: One-week treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Trial: 11515622
Drug: Two-week treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-week treatment with lansoprazole (30 mg bid), clarithromycin (500 mg bid), and amoxycillin (1 g bid)
Trial: 8890678
Drug: Diazepam (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (intravenous doses)
Trial: 6452796
Drug: Zimelidine (225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine (225 mg)
Trial: 6225313
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg)
Trial: 29551533
Drug: SQ tree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ tree SLIT-tablet (7 DU)
Trial: 29551533
Drug: SQ tree
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ tree SLIT-tablet (all doses)
Trial: 26951571
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of directly observed once‐weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maximum dose, 900 mg) (3HP‐DOT)
Trial: 26951571
Drug: 9 months
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 9 months of daily self‐administered isoniazid (maximum dose, 300 mg; 9H‐SAT)
Trial: 21602517
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of ketoconazole (a potent CYP3A4 inhibitor)
Trial: 21602517
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of erythromycin (a moderate CYP3A4 inhibitor)
Trial: 21602517
Drug: Ruxolitinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib alone and in combination with ketoconazole, erythromycin, or rifampin
Trial: 15470331
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (300 mg 3 times daily)
Trial: 11394559
Drug: Self‐administered, computer‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered, computer‐based intervention delivered in 15 brief weekly segments
Trial: 11394559
Drug: Self‐administered, computer‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered, computer‐based intervention
Trial: 11547642
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin E2 gel
Trial: 8066102
Drug: Single intracervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intracervical application of PGE2 gel